Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with histologically proven stage IIIc or stage IV melanoma who fails to qualify for curative surgery and who bears one or more tumors that are accessible for direct injection~2. Patient must have had no more than one previous systemic regimen for management of melanoma; however, adjuvant chemotherapy administered 6 months or longer before entering the trial does not count as a line of treatment~3. Absence of circulating serum neutralizing antibodies to CVA21 (titer \< 1:16)~4. At least one tumor 0.5 to 10 cm in the longest diameter must be suitable for injection and at least one tumor must be equal to or greater than 1 cm and qualified to be a target lesion for RECIST 1.1 criteria~5. Patient must have adequate hematologic, hepatic and renal function, defined as:~   * Absolute neutrophil count (ANC) \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L~  * Bilirubin \< 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) \< 2.5 x ULN~  * Serum creatinine \< 1.5 x ULN; if \> 1.5 x ULN, it must be confirmed that creatinine clearance \> 30 mL/minute~6. Serum lactate dehydrogenase (LDH) levels \< or = 1.5 x ULN~7. Male or female age 18 years or older~8. Performance status (Eastern Cooperative Oncology Group \[ECOG\]) 0 or 1~9. Estimated life expectancy of more than 6 months~10. Recovered from prior therapy with at least 4 weeks since the last exposure to chemotherapy or radiotherapy~11. Patient is able and willing to provide written informed consent to participate in the study~12. Fertile males and females must agree to the use of an adequate form of contraception, e.g., condoms for males. A negative pregnancy test is required in female patients of childbearing potential.~Exclusion Criteria:~1. Mucosal or ocular primary tumors~2. Bone metastases~3. Greater than 3 visceral metastases~4. Any visceral metastases \> 10 cm~5. Serum anti-CVA21 neutralizing titer of \> 1:16 at baseline~6. Presence of any central nervous system (CNS) tumor that has not been stable for at least 3 months off corticosteroids and confirmed by imaging~7. Tumors to be injected lying in mucosal regions or close to an airway, major blood vessel or spinal cord that, in the opinion of the Investigators, could cause occlusion into a major vessel in the case of necrosis~8. Only measurable tumor had prior local radiotherapy without subsequent nodule progression~9. Patient has received chemotherapy within the last 4 weeks prior to first injection~10. ECOG score greater than 1~11. Estimated life expectancy of less than 6 months~12. Pregnancy or breastfeeding~13. Primary or secondary immunodeficiency, including immunosuppressive disease, and immunosuppressive doses of corticosteroids (e.g., prednisolone \> 7.5 mg per day) or other immunosuppressive medications including cyclosporine, azathioprine, interferons within the past 4 weeks prior to screening~14. Positive serology for human immunodeficiency virus (HIV), hepatitis B or C~15. Full dose anticoagulation or a history of bleeding diathesis or poorly controlled bleeding in the last month prior to screening~16. Previous splenectomy~17. Presence of uncontrolled infection~18. Presence of unstable neurological disease~19. Any uncontrolled medical condition that, in the opinion of the investigator, is likely to place the patient at unacceptable risk during the study or reduce his/her ability to complete the study~20. Participation in another study requiring administration of an investigational drug or biological agent within the last 4 weeks prior to screening~21. Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent~22. Participation in any previous melanoma immunotherapy trial within 1 month prior to entry to this trial or any trial of any other investigational agent within the last month prior to entry to this trial~23. Active infections or serious general medical conditions~24. Patients with previous malignancies should only be permitted if they have been in a continued state of no evidence of disease for at least 5 years with the exception of adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of the breast, and basal cell/squamous cell skin cancer~25. Known allergy to treatment medication or its excipients and/or to the contrast medium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intratumoral injection (Type: EXPERIMENTAL): Each patient will receive 4 separate Coxsackievirus A21 (CVA21) administrations in the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day 22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a maximum of 10 sets of injections) until confirmed disease progression or development of excessive toxicity. Subjects with stable disease or better at Day 127 were eligible to receive up 9 more sets of CVA21 administrations under an extension protocol (VLA-008).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete